66 related articles for article (PubMed ID: 22124126)
1. An antitumor cellular vaccine based on a mini-membrane IgE.
Nigro EA; Soprana E; Brini AT; Ambrosi A; Yenagi VA; Dombrowicz D; Siccardi AG; Vangelista L
J Immunol; 2012 Jan; 188(1):103-10. PubMed ID: 22124126
[TBL] [Abstract][Full Text] [Related]
2. Antitumor IgE adjuvanticity: key role of Fc epsilon RI.
Nigro EA; Brini AT; Soprana E; Ambrosi A; Dombrowicz D; Siccardi AG; Vangelista L
J Immunol; 2009 Oct; 183(7):4530-6. PubMed ID: 19748979
[TBL] [Abstract][Full Text] [Related]
3. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
[TBL] [Abstract][Full Text] [Related]
4. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC
Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449
[TBL] [Abstract][Full Text] [Related]
7. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
8. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.
Chen CH; Wang TL; Ji H; Hung CF; Pardoll DM; Cheng WF; Ling M; Wu TC
Gene Ther; 2001 Jan; 8(2):128-38. PubMed ID: 11313782
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with a Modified Vaccinia Virus Ankara-based vaccine protects mice from allergic sensitization.
Albrecht M; Suezer Y; Staib C; Sutter G; Vieths S; Reese G
J Gene Med; 2008 Dec; 10(12):1324-33. PubMed ID: 18816482
[TBL] [Abstract][Full Text] [Related]
10. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
[TBL] [Abstract][Full Text] [Related]
11. Protection of IgE-mediated allergic sensitization by active immunization with IgE loops constrained in GFP protein scaffold.
Chen SS; Barankiewicz T; Yang YM; Zanetti M; Hill P
J Immunol Methods; 2008 Apr; 333(1-2):10-23. PubMed ID: 18281056
[TBL] [Abstract][Full Text] [Related]
12. [Construction and the immunogenicity of the recombinant Modified Vaccinia Virus Ankala co-expressing ORF4, ORF5 and ORF6 genes of porcine reproductive and Respiratory Syndrome Virus NJ-a strain].
Zheng QS; Bi ZX; Li P; Chen DS; Chen PY
Wei Sheng Wu Xue Bao; 2007 Apr; 47(2):345-9. PubMed ID: 17552247
[TBL] [Abstract][Full Text] [Related]
13. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
[TBL] [Abstract][Full Text] [Related]
14. Assessment of three human FcepsilonRI-transfected RBL cell-lines for identifying IgE induced degranulation utilizing peanut-allergic patient sera and peanut protein extract.
Ladics GS; van Bilsen JH; Brouwer HM; Vogel L; Vieths S; Knippels LM
Regul Toxicol Pharmacol; 2008 Aug; 51(3):288-94. PubMed ID: 18534732
[TBL] [Abstract][Full Text] [Related]
15. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
16. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
17. IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines.
Reali E; Greiner JW; Corti A; Gould HJ; Bottazzoli F; Paganelli G; Schlom J; Siccardi AG
Cancer Res; 2001 Jul; 61(14):5517-22. PubMed ID: 11454701
[TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.
Loukinov D; Ghochikyan A; Mkrtichyan M; Ichim TE; Lobanenkov VV; Cribbs DH; Agadjanyan MG
J Cell Biochem; 2006 Aug; 98(5):1037-43. PubMed ID: 16741971
[TBL] [Abstract][Full Text] [Related]
19. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.
Triulzi C; Vertuani S; Curcio C; Antognoli A; Seibt J; Akusjärvi G; Wei WZ; Cavallo F; Kiessling R
Cancer Res; 2010 Oct; 70(19):7431-41. PubMed ID: 20823150
[TBL] [Abstract][Full Text] [Related]
20. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone.
Meseda CA; Elkins KL; Merchlinsky MJ; Weir JP
J Infect Dis; 2002 Oct; 186(8):1065-73. PubMed ID: 12355355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
